ClinicalTrials.gg
RecruitingNCT07511842REST-KneeUpdated Apr 6, 2026

REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes

An interventional study of Knee Extension Brace (Zimmer-type) and Early Mobilization (Standard Care) in Total Knee Arthroplasty, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Pain, Postoperative with a site in Canada — 38 open to participants now, 42 under way, 3 of them phase 3. Pain, Postoperative · Canada.

Planned enrollment
62nd of 175
106 · median 82
Started
2026
with 3 others
No phase
94 of 190
17 open now
Primary completion
2027-12
later than 35 of 41 live
Registered
189th of 190
by date

Among the 190 studies in Pain, Postoperative with a site in Canada, this one is the 62nd largest by planned enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2026, is one of 94 with no phase, reaches primary completion later than 35 of the 41 other live ones, and was the 189th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

38 of the 190 studies in Pain, Postoperative with a site in Canada are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Pain, Postoperative with a site in Canada, or all of them as a file.
02

Study summary

Postoperative pain following total knee arthroplasty (TKA) is often difficult to manage, particularly with the increasing use of outpatient surgery where patients recover at home. This study aims to evaluate whether wearing a knee extension brace for the first 72 hours after surgery can reduce pain and improve recovery.

This pilot randomized controlled trial will compare two groups of patients undergoing primary unilateral TKA: one group will wear an extension brace continuously for 72 hours after surgery, while the control group will follow standard care with early mobilization. Participants will be followed for up to 12 months.

The primary objective of this pilot study is to assess the feasibility of conducting a larger trial, including recruitment rates, adherence to the intervention, follow-up completion, safety, and acceptability. Clinical outcomes will also be explored, including pain at 2 and 6 weeks after surgery (measured using a visual analog scale), knee function, range of motion, opioid consumption, complications, healthcare use, and quality of life.

The study hypothesizes that short-term immobilization of the knee in full extension will reduce postoperative pain and may improve early recovery outcomes. Findings from this pilot study will inform the design of a larger definitive trial and may contribute to improving postoperative care and pain management after knee replacement surgery.

Read the detailed description

Postoperative pain following total knee arthroplasty (TKA) remains a significant clinical challenge, particularly in the context of increasing use of outpatient surgical pathways. Optimizing early postoperative pain management is essential to improve recovery, reduce unplanned healthcare utilization, and support enhanced recovery after surgery (ERAS) principles.

This study aims to evaluate the effect of short-term postoperative immobilization using a knee extension brace (Zimmer-type) worn continuously for 72 hours following primary unilateral TKA on postoperative pain at 2 and 6 weeks, measured using the Visual Analog Scale (VAS). The study hypothesizes that maintaining the knee in full extension during the immediate postoperative period will reduce pain and improve early recovery outcomes.

Study Design

This study is a pilot randomized controlled trial with a 1:1 allocation ratio and a single-blind design, in which outcome assessors are blinded to group allocation. The study is conducted at a single center (CHUS, Estrie, Canada).

Participants undergoing primary unilateral TKA will be randomized into one of two groups:

Intervention group: immobilization of the operated knee in full extension using a Zimmer-type brace for 72 hours postoperatively, followed by standard physiotherapy care.

Control group (standard of care): no restriction in movement, with early supervised mobilization according to usual physiotherapy practice.

The study adopts a pragmatic approach, allowing variability in physiotherapy delivery to reflect real-world clinical practice and enhance external validity. Timing and frequency of physiotherapy sessions will be recorded.

Study Objectives

The primary objective of this pilot study is to assess feasibility, including:

Recruitment rate and participant flow (inclusion, exclusion, refusal) Follow-up completion rate (target ≥80%) Intervention adherence (target ≥80% compliance in the intervention group) Safety, based on postoperative complication rates (including deep vein thrombosis, wound complications, and joint stiffness) Acceptability of the intervention and study procedures among patients and healthcare providers Estimation of variance in VAS pain scores to inform sample size calculation for a future definitive trial

The clinical primary outcome is postoperative pain at 2 and 6 weeks measured using the VAS, reported as mean differences between groups with 95% confidence intervals.

Secondary clinical outcomes include:

Knee range of motion (ROM) Postoperative opioid consumption Postoperative complications Emergency department visits and hospital readmissions Health-related quality of life (EQ-5D-5L) Knee function (Knee Society Score [KSS] and Functional KSS) Blood loss (hemoglobin levels) Postoperative inflammation (C-reactive protein) Study Population

The study population includes adults aged 18 years and older undergoing primary unilateral TKA for knee osteoarthritis at CHUS.

Key exclusion criteria include:

Known thrombophilia or bleeding disorders History of thromboembolic events Contraindications to brace use (e.g., material allergy) Revision or constrained knee prostheses Use of continuous postoperative nerve block infusion Sample Size

The pilot study aims to recruit 106 participants (53 per group) over an 18-month period, representing approximately 15% of the estimated sample size required for a definitive trial. Data from this pilot will be used to refine sample size calculations.

Recruitment and Procedures

Eligible patients will be identified during orthopedic consultations and approached for participation. After informed consent, baseline data (demographics, clinical characteristics, and preoperative measures) will be collected.

Randomization will occur on the day of surgery. The intervention will be applied by the orthopedic surgeon.

Follow-up assessments will occur at:

2-5 days postoperatively 2 weeks 6 weeks 3 months 12 months

Data collected include patient-reported outcomes, clinical assessments, laboratory values, and healthcare utilization. Participants in the intervention group will record brace wear time and opioid consumption using daily logs.

Data Collection and Outcomes

Pain will be assessed using the Visual Analog Scale (VAS). Additional outcomes include ROM measured with a goniometer, validated questionnaires (KSS, FKSS, EQ-5D-5L), laboratory markers (hemoglobin and C-reactive protein), and postoperative complications.

Opioid consumption and brace adherence will be self-reported using patient diaries. Healthcare utilization (emergency visits and readmissions) will be collected retrospectively.

Data Analysis

Feasibility outcomes will be analyzed descriptively using an intention-to-treat approach. Recruitment, adherence, and completion rates will be reported with 95% confidence intervals.

Comparisons between groups for exploratory clinical outcomes will be conducted using appropriate statistical tests depending on data distribution. This pilot study is not powered for definitive efficacy conclusions but will provide estimates to guide a larger trial.

03

Conditions studied

  • Total Knee Arthroplasty

Browse trials for

Keywords

  • total knee arthroplasty
  • knee replacement
  • postoperative pain
  • Knee immobilization
  • Extension brace
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Person undergoing primary unilateral TKA for knee osteoarthritis at CHUS

Exclusion criteria

Exclusion Criteria:

  • Known thrombophilia or bleeding disorders
  • History of thromboembolic events
  • to brace use (e.g., material allergy)
  • Revision or constrained knee prostheses
  • Use of continuous postoperative nerve block infusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Extension Brace Group

    Participants will undergo postoperative immobilization of the operated knee in full extension using a Zimmer-type knee brace for 72 hours following primary total knee arthroplasty, followed by standard physiotherapy care.

    Device: Knee Extension Brace (Zimmer-type)

  • Active comparator
    Standard Care Group

    Participants will receive standard postoperative care consisting of early mobilization without movement restriction and supervised physiotherapy according to usual clinical practice.

    Other: Early Mobilization (Standard Care)

Interventions

  • DeviceKnee Extension Brace (Zimmer-type)

    Participants will wear a knee extension brace maintaining the operated knee in full extension for 72 hours following surgery. The brace is to be worn continuously (target ≥23 hours per day), after which standard physiotherapy care will be initiated.

  • OtherEarly Mobilization (Standard Care)

    Participants will receive standard postoperative care, including early mobilization without restriction and supervised physiotherapy according to usual clinical practice.

06

What researchers measure

Primary outcomes

  1. Study feasibility

    Feasibility will be assessed by recruitment rate, follow-up completion (target ≥80%), intervention adherence (target ≥80%), and safety based on postoperative complications.

    Time frame: Up to 18 months (study completion)

Secondary outcomes

  1. Postoperative Pain (VAS)

    Pain measured using a 100-mm Visual Analog Scale.

    Time frame: 2 weeks, 6 weeks, 3 months, 12 months

  2. Knee Range of Motion (ROM)

    Measured with a goniometer.

    Time frame: 2 weeks, 6 weeks, 3 months, 12 months

  3. Opioid Consumption

    Self-reported number of tablets consumed.

    Time frame: Up to 6 weeks

  4. Postoperative Complications

    Includes wound complications, infection, and thromboembolic events.

    Time frame: Up to 6 weeks

  5. Healthcare Utilization

    Emergency visits and hospital readmissions.

    Time frame: Up to 6 weeks

  6. Quality of Life (EQ-5D-5L)

    Standardized questionnaire.

    Time frame: Baseline, 2 weeks, 6 weeks, 3 months, 12 months

  7. Knee Function (KSS/FKSS)

    Validated functional scores.

    Time frame: Baseline, 6 weeks, 3 months, 12 months

  8. Inflammation (CRP)

    2-5 days, 2 and 6 weeks

    Time frame: Blood test marker.

  9. Hemoglobin

    Blood test.

    Time frame: 2-5 days and 6 weeks

  10. Global Improvement (PGI-C)

    Patient-reported change.

    Time frame: 2 and 6 weeks

  11. Brace Compliance

    Self-reported hours of wear.

    Time frame: First 72 hours

  12. Perceived Safety

    Study-specific questionnaire.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
  • CIUSSS de l'Estrie-CHUS, 3001, 12e Ave Nord, Sherbrooke, Qc, Canada, J1H 5N4
    Sherbrooke, Quebec J1K 2P2, Canada
    Recruiting
    • Sonia Bédard, Masters · Contactsonia.bedard2@usherbrooke.ca · 1-819-346-1110
    • Emile Loiselle, MD · Sub investigator
    • Annie Deshaies, MD FRCSC · Sub investigator
    • Loïc St-Laurent-Lebeux, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be made available upon reasonable request to the corresponding investigator.

Time frame: Data will be available beginning 6 months following publication of the primary results and ending 5 years after publication.

Access criteria: Access will be granted to researchers who provide a methodologically sound proposal. Requests will be reviewed by the study team, and data sharing will require a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 21 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07511842
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Mar 3, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 6, 2026

Study contacts

Sonia Bedard, Masters
Contact
sonia.bedard2@usherbrooke.ca
1-819-346-1110 ext. 13927
Yoan Bourgeault-Gagnon, MD FRCSC
Contact
yoan.bourgeault-gagnon@usherbrooke.ca
Yoan Bourgeault-Gagnon, MD FRCSC
principal investigator · Université de Sherbrooke
François Vaillancourt, MD FRCSC
study director · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion